A Team of University of Maryland Students Just Wowed NIH With … – Washingtonian.com

Its a cool time for young people interested in changing health care. Tech is more accessible, and it no longer takes multiple degrees to make a difference. Thats certainly the case for a team of University of Maryland bioengineering undergraduate students, who just took home the top prizea $20,000 awardin theDesign by Biomedical Undergraduate Teams (DEBUT) competition by the National Institutes of Healths (NIH) National Institute of Biomedical Imaging and Bioengineering (NIBIB).

The teamwhich was made up of seven students in UMDs class of 2020were up against 41 entries from teams across the country that had designed prototypes of products to advance technology and improve human health. UMDs winning prototype, a wearable EEG monitor, is intended to help diagnose Alzheimers disease.

Dhruv Patel, who led the UMD team along with Chris Look, says that he was inspired to look for innovation in Alzheimers after his grandfather was diagnosed with the disease.

I pursued research into the disease and how current mechanisms fail to diagnose it in an earlier stage, says Patel. I saw there was improvement to be made, and so I set out to make that improvement.

To create their prototype, the students used an OpenBCI portable EEG monitor as their base, then plugged in clinical data obtained from international medical institutions into machine learning tools to enable the device to tell healthy brain waves apart from an Alzheimers patients brain waves. In one of the tests the students designed, the monitor-wearer hears two different tonesone at a high frequency, the other lowand then the EEG monitor reads their responsive brain waves to determine whether they are reading as an Alzheimers patient would.

The devicewhich won first place ahead of a brain surgery mapping tool by the second place team from Arizona State University and a cornea transplant device by the third place team from Johns Hopkins Universitycaught the attention of the judges because it both addressed a widespread problem in health care and has the potential to make a big difference in how that problem is approached in the future.

Such a device that can easily be used by a clinician to determine that an individual is inflicted with Alzheimers disease before the patient displays clinical symptoms can both guide the clinician in the treatment of the patient and allow the patient and their family time to prepare, says NIBIBs program director for interdisciplinary training Zeynep Erim.The impact for society is immense.

Patel says that the $20,000 award will be invested in their newly filed LLC, Synapto. Patel and his Synapto co-founder, Look, are planning to pursue a patent for their technology within the next year. They also plan to continue collecting data from medical institutions around the globe to improve their devices accuracy in identifying Alzheimers brain waves, before eventually moving into clinical trials.

Correction: A former version of this story incorrectly identified Zeynep Erim as Erim Zeynep.

Associate Editor

Caroline Cunningham joined Washingtonian in 2014 after moving to the DC area from Cincinnati, where she interned and freelanced for Cincinnati Magazine and worked in content marketing. She currently resides in College Park.

Read the rest here:
A Team of University of Maryland Students Just Wowed NIH With ... - Washingtonian.com

Bruno Major Completes ‘A Song For Every Moon’ Project – Clash Magazine

Bruno Major has shared the final part of his new project 'A Song For Every Moon'.

The composer kicked off the project earlier this year, sharing new material bit by bit, piece by piece.

The final piece of the puzzle is new track 'On Our Own', a song partly prompted by the death of the songwriter's grandmother.

A hushed and tender ballad, it's an intimate offering from Bruno Major. He explains: I wrote this after a conversation with my mother when my Granny died. Her death sparked a personal journey through Agnosticism, Atheism and through the other side, and writing 'On Our Own' helped me understand how I felt about existence and religion. I think this is the song that I am most proud of.

Check out 'A Song For Every Moon' in its entirety below.

Related: Full Moon - The Songwriting Quest Of Bruno Major

Join us onVero, as we get under the skin of global cultural happenings. FollowClash Magazineas we skip merrily between clubs, concerts, interviews and photo shoots. Get backstage sneak peeks and a true view into our world as the fun and games unfold.

Buy Clash Magazine

More here:
Bruno Major Completes 'A Song For Every Moon' Project - Clash Magazine

Taconic Biosciences Sponsors Custom Model to Support Kabuki Syndrome, a Rare Disorder Causing Intellectual … – GlobeNewswire (press release)

HUDSON, N.Y., Aug. 31, 2017 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in genetically engineered rodent models and associated services, is funding the development of a custom mouse model to study Kabuki syndrome, a rare genetic disorder. Taconic is donating model generation services as a third-time sponsor of the Rare Disease Science Challenge, BeHEARD. Hosted by the Rare Genomics Institute, the Rare Disease Science Challenge is an annual event in which industry sponsors donate services to accelerate rare disease research.

Characterized by mild to moderate intellectual disability, stunted growth, immune dysregulation, and hearing loss, Kabuki syndrome is caused by mutations in the KMT2D or KDM6A genes. Taconic will use CRISPR/Cas 9 gene editing technology to develop the first Kmt2d missense mouse model of Kabuki syndrome and generate a cohort of mice for study. In parallel, Taconic will cryopreserve and store the mouse line.

Taconic recognizes the vital role mouse models play in understanding the mechanisms of rare diseases and the challenges of funding their research, said Bob Rosenthal, CEO, Taconic Biosciences. Taconic is committed to advancing rare disease research through efforts such as sponsorship of the BeHEARD challenge and donation of an integrated solution of model generation, breeding and cryopreservation capabilities.

Teresa Luperchio, PhD, a postdoctoral fellow in the laboratory of Hans Bjornsson, MD, PhD, director of the Epigenetics and Chromatin Clinic, McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, will employ the Taconic model. Dr. Bjornssons lab previously characterized a mouse model carrying a loss-of-function variant of the Kmt2d gene and demonstrated reversal of some learning and memory deficits using therapeutic strategies. However, the initial mouse line models only a subset of individuals with Kabuki syndrome. Taconic will generate a Kabuki syndrome mouse model based on a patient-specific missense mutation. This will enable investigators to assess whether therapies they are developing can reverse disability in a wider spectrum of the Kabuki syndrome patient population.

The model will be invaluable in moving the field closer to treating what has been viewed as an untreatable disorder. Experience with our first mouse model showed that for patients with the KMT2D mutation, the disease may be treatable in humans, Dr. Bjornsson said. We hope the Taconic model will demonstrate this capability in an expanded patient population, allowing us to employ a single therapeutic strategy for all Kabuki syndrome type 1 patients.

Taconics ability to develop a patient-specific model was essential. Generating a model that closely represents what is seen in patients is critical for translating our findings from the bench to the clinic, Dr. Luperchio says.

To learn more about Taconics custom model generation, please call 1-888-TACONIC (888-822-6642) in the US or +45 70 23 04 05 in Europe, or email info@taconic.com.

To learn about the BeHEARD Project, visit http://www.raregenomics.org/beheard-competition/.

About Taconic Biosciences, Inc.Taconic Biosciences is a global leader in genetically engineered rodent models and services. Founded in 1952, Taconic helps biotechnology companies and institutions acquire, custom generate, breed, precondition, test, and distribute valuable research models worldwide. Specialists in genetically engineered mouse and rat models, precision research mouse models, and integrated model design and breeding services, Taconic operates three service laboratories and six breeding facilities in the U.S. and Europe, maintains distributor relationships in Asia and has global shipping capabilities to provide animal models almost anywhere in the world.

Follow this link:
Taconic Biosciences Sponsors Custom Model to Support Kabuki Syndrome, a Rare Disorder Causing Intellectual ... - GlobeNewswire (press release)

Climate Smart Crops: A Necessity for Future Food & Nutrition Security – Inter Press Service

Development & Aid, Economy & Trade, Editors' Choice, Featured, Food & Agriculture, Global, Green Economy, Headlines, Poverty & SDGs, TerraViva United Nations | Opinion

Bev Postma is CEO of HarvestPlus

Golden rice is fortified rice to reduce shortage of dietary vitamin A

WASHINGTON DC, Aug 31 2017 (IPS) - Climate change is taking a severe toll on farmers, as they watch their livelihoods disappear with the onslaught of floods, droughts and rising sea levels and temperatures. With agriculture currently employing over 1.3 billion people throughout the world, or close to 40 percent of the global workforce, it is imperative that we incorporate climate resilience into all aspects of crop breeding and food innovation.

Developing ways to improve staple crops so that they can withstand some of the adverse effects of climate change will ensure food security and agricultural livelihood for generations to come.

A recent report from the International Food Policy Research Institute (IFPRI) found that at current rates of climate change, it is likely that global food production will decline by two percent every decade until at least 2050, just as the worlds population is expected to reach 9.7 billion people.

As a result of these factors, people may be forced to eat fewer fruits, vegetables, and red meat products because their availability may be scarce and prices may rise accordingly. Access to food may also be limited by climate-related vulnerabilities in transportation, storage, and processing.

Projection models from the World Bank likewise show that by the 2030s-2040s, between 40 to 80 percent of cropland used to grow staple crops like maize, millet and sorghum could be lost due to the effects of higher temperatures, drought and aridity.

At the same time, increased levels of CO2 in the atmosphere are already decreasing the nutritional quality of crops lowering their concentrations of vital micronutrients like zinc and iron. In a 2014 study on CO2 and crop nutrition, Samuel Myers of Harvard University and his colleagues determined that the CO2 levels in the second half of this century would likely reduce the levels of zinc, iron, and protein in wheat, rice, peas, and soybeans.

Some two billion people live in countries where citizens receive more than 60 percent of their zinc or iron from these foods. Many already suffer from diets that lack enough of these important minerals, and increased deficiencies of these vital nutrients would have even more devastating health consequences.

A new technology known as biofortification the process of increasing the nutrient content of staple food crops is a promising tool in the global effort to mitigate these trends.

Many of the effects of climate change are already being felt. Increased drought and aridity are now a reality in Somalia, Kenya and Ethiopia, leading to widespread harvest losses and livestock death. As a result, malnutrition levels in the area have skyrocketed. In Somalia alone, the UN says more than six million people are in need of urgent help.

Though climate change continues to progress at an advanced pace, researchers and policymakers can help offset some of the negative impact on farmers by focusing on crop adaptation strategies. Organizations like HarvestPlus and our global partners recognize the necessity of climate resilience and our scientists, plant breeders and country teams are working daily to scale out more climate-resilient crops.

At the International Center for Tropical Agriculture in Palmira, Colombia, researchers are developing beans that can beat the heat. Often referred to as the meat of the poor, beans offer a crucial source of vitamins and protein as well as income for millions of people, particularly in Africa and Latin America.

But climate modeling suggests that, over the coming decades, higher temperatures will threaten bean production, reducing yields and quality. Moreover, heat stress could diminish the area for growing beans by up to 50% in eastern and central Africa by the year 2050.

By identifying elite lines of beans that show strong tolerance to heat up to 30 degrees Celsius breeders can develop more productive, nutritionally improved beans that are resilient even in harsh growing conditions.

Indeed, climate resistant traits are integral to all 150 varieties of the 12 staple crops we and our partners have developed. We run extensive tests to ensure crops will be successful, from stress tests in the field mimicking intense climate conditions, to studies in laboratories.

Under repeatable stress conditions, we generate an environment for testing which allows breeding for climate smart, robust varieties with high micronutrient and high yield stability.

The traits bred into our crops are virus, disease and pest resistance, as well as drought and heat tolerance. These selective plant breeding techniques are just one means of securing agriculture in areas vulnerable to climate change, but we have to do more.

As climate change continues to play a dominant role in agriculture and food security, we have to remain committed to continued research to be sure people in rural communities receive the most nutritious and resilient crop varieties available.

With ongoing crises of famine in five countries stretching from Africa to the Middle East, farmers and vulnerable populations are relying on policymakers, scientists and aid workers to provide the necessary tools to mitigate hunger and prevent additional harvest losses.

Read more:
Climate Smart Crops: A Necessity for Future Food & Nutrition Security - Inter Press Service

Balance and Gait Problems can be Improved using Avatars – Anti Aging News

Use of brain-computer interface, virtual avatar could help people with gait disabilities

World Health and A4M have been following gait problems for years in terms of the way balance effect falling and the progression of aging. The role of the American Academy of Anti-Aging Medicine is to support investigators in their goal of attenuation and/or reversing some of the aging process.

The study, funded by the National Institute of Neurological Disease and Stroke, was published this week inScientific Reports. Senior author and researcher Jose Luis Contreras-Vidal is the professor of electrical and computer engineering at University of Houstons Noninvasive Brain-Machine Interface System Laboratory. He is also the site director of the BRAIN Center (Building Reliable Advances and Innovation in Neurotechnology), a National Science Foundation Industry/University Cooperative Research Center. His teams studies are the first to prove that using an interface between a proprietary computer program and a human brain depicting another person walking (avatar) may help balance patients improve gait and return to normal walking following spinal cord or other injury or cerebral vascular injury (stroke). He says that this is the first to involve humans, even though other studies on other primates have been perform previously.

Contreras-Vidal and researchers performed the study by using three trials with 80 healthy graduate students in the UH Department of Electrical and Computer Engineering to provide baseline data. The subjects walked on a treadmill while watching the avatar on a large screen in order to provide increased visual input while wearing a 64-channel EEG skull cap in addition to sensors on ankle, knee and hip joints. The non-invasive brain monitoring helped determine what parts of the brain are involved in walking. They then created an algorithm for a computer-brain interface.

His team wrote. "Voluntary control of movements is crucial for motor learning and physical rehabilitation," "Our results suggest the possible benefits of using a closed-loop EEG-based BCI-VR (brain-computer interface-virtual reality) system in inducing voluntary control of human gait." Up till this point, no one had researched whether a computer assisted algorithm and avatar might actually be effective in promoting better gait, balance and stability.

The subject was connected to the computer via the skull cap and sensors so that the interface caused the avatar on the screen to mimic the subject. The study reported increased activity in the posterior parietal cortex and the inferior parietal lobe, as well as the anterior cingulate cortex; all of which are involved in motor memory. Eventually the subject was actually able to control the avatar with their own brain although much less accurately. Future studies will likely be more accurate as software and interfaces improve. Contreras-Vidal said, "It's like learning to use a new tool or sport," he said. "You have to understand how the tool works. The brain needs time to learn that." The subject of Contreras-Vidal upcoming Ph.D. dissertation is the use of this protocol with actual patients. "The appeal of brain-machine interface is that it places the user at the center of the therapy," Contreras-Vidal said. "They have to be engaged, because they are in control."

Read the rest here:
Balance and Gait Problems can be Improved using Avatars - Anti Aging News

White Lotus Products Available on CompleteBeautyStore.com – Benzinga

White Lotus, a company known for its products that adhere to the principles of ancient Chinese medicine to provide anti-aging solutions, announced its products are now ready to be ordered from CompleteBeautyStore.com.

Boca Raton (PRWEB) August 29, 2017

White Lotus, a company known for its products that adhere to the principles of ancient Chinese medicine to provide anti-aging solutions, announced its products are now ready to be ordered from CompleteBeautyStore.com.

The company focuses on producing and distributing holistic anti-aging products. Founded in 2007, White Lotus is different from mainstream beauty companies in that its products are all based on principles of ancient Eastern medicine. Anthony and Kamila Kingston started the Australia-based company after traveling around the world to learn about Chinese medicine. The company's products are now on specialty beauty sites as well as major retail platforms like Amazon.com and Jet.com.

"We're excited to announce White Lotus products will be available from CompleteBeautyStore.com," said Anthony Kingston. "As we focus on expanding our reach in the US market, we want to make our products available to all consumers. White Lotus offers a unique approach in the crowded beauty and cosmetics sector by offering holistic anti-aging solutions that have stood the test of time."

White Lotus is filling a demand in the market for Chinese medicine and acupuncture products. These are designed to enhance skin health, resolve chronic pain problems, prevent hair loss, and eliminate signs of aging such as scars, marks, and wrinkles. The company has developed a reputation for holding impeccable standards of research and testing of its products. Therefore, it can deliver on its promise to provide users with healthier, smoother skin.

White Lotus has a popular line of anti-aging serums. These products are designed to remove aging signs such as cellulite and stretch marks. The jade product line is also popular and gaining traction in the US market. For instance, the jade roller improves lymphatic drainage, skin smoothness and microcirculation, offering users the kind of luxury and relaxation typically reserved for people who come to one of Australia's White Lotus clinics.

"It's our goal to introduce more customers to tried-and-true Eastern principles of skin care," said Kingston. "This new partnership with CompleteBeautyStore.com will help us reach a broader audience."

For more information about White Lotus and its products, visit http://www.whitelotusantiaging.com.

For the original version on PRWeb visit: http://www.prweb.com/releases/2017/08/prweb14635833.htm

Read more here:
White Lotus Products Available on CompleteBeautyStore.com - Benzinga

Discovery of a New Compound Turns on a Longevity Gene in Mice – Anti Aging News

New compound provides an observed 90% increase in the activation of the gene's activation in the animal's heart tissue

The University of Hawaii Cancer Center has developed a compound called Astaxanthin that turns on whats called the FOX03 'Longevity Gene' in mice. Their scientists measured an almost a 90% increase in the activation of the gene in the animals' heart tissue.

In a joint venture, The University of Hawaii John A. Burns School of Medicine ("JABSOM") and Cardax, Inc. ("Cardax") (OTCQB:CDXI), a Honolulu based life sciences company revealed their promising results toward a new anti-aging therapy

Dr. Bradley Willcox, MD, Professor and Director of Research at the Department of Geriatric Medicine, JABSOM, and Principal Investigator of the National Institutes of Health-funded Kuakini Hawaii Lifespan and Healthspan Studies states, "All of us have the FOXO3 gene, which protects against aging in humans," said. "But about one in three persons carry a version of the FOXO3 gene that is associated with longevity. By activating the FOXO3 gene common in all humans, we can make it act like the "longevity" version. Through this research, we have shown that Astaxanthin "activates" the FOXO3 gene," said Willcox.

"This preliminary study was the first of its kind to test the potential of Astaxanthin to activate the FOXO3 gene in mammals," said Dr. Richard Allsopp, PhD, Associate Professor, and researcher with the JABSOM Institute of Biogenesis Research.

Experiments with the mice the control group was fed regular food and the other group was either a low or high amount of Astaxanthin compound CDX-085 provided by Cardax. As expected the group with higher doses gained the greatest increase in the FOXO3 gene in their heart tissue. "We found a nearly 90% increase in the activation of the FOXO3 "Longevity Gene" in the mice fed the higher dose of the Astaxanthin compound CDX-085," said Dr. Allsopp.

"This groundbreaking University of Hawaii research further supports the critical role of Astaxanthin in health and why the healthcare community is embracing its use," said David G. Watumull, Cardax CEO. "We look forward to further confirmation in human clinical trials of Astaxanthin's role in aging."

"We are extremely proud of our collaborative efforts with Cardax on this very promising research that may help mitigate the effects of aging in humans," said Vassilis L. Syrmos, Vice President of Research at the University of Hawaii. "This is a great example of what the Hawaii Innovation Initiative is all about -- when the private sector and government join forces to build a thriving innovation, research, education and job training enterprise to help diversify the state's economy."

Life sciences company Cardax, Inc. looks forward to further confirmation in human clinical trials of Astanxanthin's potential role as an anti-aging therapy.

Dr. Michael J. Koch, Editor withwww.WorldHealth.net and for Dr. Ronald Klatz, DO, MD President of the A4M has 28,000 Physician Members, has trained over 150,000 Physicians, health professionals and scientists in the new specialty of Anti-aging medicine. Estimates of their patients numbering in the 100s of millions World Wide that are living better stronger, healthier and longer lives. A4M physicians are now providing advanced preventative medical care for over 100 Million individuals worldwide who now recognize that aging is no longer inevitable.

The rest is here:
Discovery of a New Compound Turns on a Longevity Gene in Mice - Anti Aging News

Grey’s Anatomy: Jo Is Desperate for Family Without Stephanie Around – TV Guide

Now PlayingGrey's Anatomy: How Will Jo Manage Without Stephanie?

Poor Jo!

That's not a statement we use much in relation to Grey's Anatomy, but we have to admit that homegirl has had it rough the past couple of seasons. On top of losing her fiance, drama causing her to fall behind in the residents program and her coworker falling in love with her, Jo's (Camilla Luddington) best friend is now leaving Grey Sloan to find herself.

That leaves one lonely Jo running around the hospital, and that's pretty damn sad. Stephanie (Jerrika Hinton) was like a sister to Jo, Luddington told TV Guide at the Television Critics Association summer press tour. However, with Stephanie gone Jo will be looking for someone else to lean on.

Grey's Anatomy: Catherine Almost Sidelined Bailey Over Karev's Assault

"I think Jo is going to try and attempt to lean on Ben a bit this season," Luddington confessed. "Is it successful? I don't know. I think she's trying to pull anyone close to her and that's another resident...As for other women, I don't know yet. That'll be interesting."

See if Jo gets a new BFF when Grey's Anatomy returns for a two-hour premiere on Thursday, Sept. 28 at 8/7c on ABC.

Continue reading here:
Grey's Anatomy: Jo Is Desperate for Family Without Stephanie Around - TV Guide

Is Sara Ramirez Returning to Grey’s Anatomy For Season 14? – SheKnows.com

Share Pin Share Tumble

Combined comments & shares on social media

Could the upcoming season of Grey's Anatomy get any better? We've already received enough incredible casting news to completely blow our minds, and now there are rumors that Sara Ramirez could be returning to the hit show to reprise her role as Callie Torres.

More: Jesse Williams' Insta Is Making Us So Hungry for Grey's Anatomy

But don't hold your breath, Grey's fans. According to executive producer Debbie Allen, "there are no plans at the moment" for Ramirez to return to the series, even for a guest role, during Season 14.

"We love her and we miss her, [but] theres been no discussion of it," Allen added.

We probably shouldn't have gotten our hopes up. But from the moment we learned that Marika Dominczyk, who played Arizona's most recent girlfriend on the show, won't be returning for the upcoming season, we couldn't help but wonder who would pick up the pieces of newly single Arizona's broken heart. And who better than her old flame, Callie? They were so great when they were together. We need them back together.

More: Using Only 9 Words, Meredith Just Destroyed Fans During the Grey's Anatomy Finale

Ramirez starred in the show up until Season 12, when she was written out because Callie announced she was relocating to take a job in New York.

"Im deeply grateful to have spent the last 10 years with my family at Greys Anatomy and ABC, but for now, Im taking some welcome time off," Ramirez said at the time. "[Series creator] Shonda [Rhimes has] been so incredible to work for, and we will definitely continue our conversations."

More: Grey's Anatomy's Finale Had a Sad Goodbye but These Deaths Were Way Worse

So far, though, those conversations haven't continued, at least to the point of getting Ramirez back on the show. Fans will just have to keep waiting and hoping, we guess.

Read the rest here:
Is Sara Ramirez Returning to Grey's Anatomy For Season 14? - SheKnows.com

Grey’s Anatomy stars send love to Houston – EW.com

The doctors of Greys Anatomy are sharing theirlove for Houston on Twitter.

Debbie Allen, who portrays Dr. Catherine Avery on the ABC show, posted a video to her Twitter account Monday alongsideChandra Wilson (Chief Miranda Bailey) and one of the shows writers Meg Marinis,to express well wishes for those facing dangerous weather conditions in Houston, Texas due to tropical storm Harvey.

Houston, we love you and we are thinking about you. From all of us at Greys Anatomy, say the three women in the clip. Allen, who is from Houston, also added a caption to the short video that shares a link to the Red Cross site, encouraging people to donate to the flooded city: To Houston from @GreysABC Help here: http://redcross.org.

RELATED:How to help the victims of Hurricane Harvey

The actress had previously tweeted a still from a news report with a caption, My hometown Houston God Speed. The photo shows victims of the flood being aided by good samaritan efforts after they had become trapped due to treacherous conditions and heavy rainfall.

Harvey has dumped some 25 inches of rain on Houston two days after the then-hurricane landfall northeast of Corpus Christi (around 220 miles southeast of Houston) Friday night. The extreme flooding has left many Houston residents stranded in their homes while emergency and rescue crews scramble to reach the overwhelming number of people calling for aid.

Greys Anatomy returns for its 14th season onThursday, Sept. 28 at 8 p.m. ET on ABC.

Read the original here:
Grey's Anatomy stars send love to Houston - EW.com

Puma Biotechnology, Inc. (PBYI): From Top to Bottom – StockNewsJournal

Puma Biotechnology, Inc. (PBYI) is an interesting player in the Healthcare space, with a focus on Biotechnology. The stock has been active on the tape, currently trading at $92.05, down from yesterdays close by -2.23%. Given the stocks recent action, it seemed like a good time to take a closer look at the companys recent data.

Fundamental Analysis

Money managers are always interested in a company that can find the right recipe of fundamental data because it reflects something important going on underneath the surface. Puma Biotechnology, Inc. (PBYI) currently trades with a market capitalization of $3.36 Billion.

The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base. For PBYI, the company currently has $80.82 Million of cash on the books. You can get a sense of how sustainable that is by a levered free cash flow of $-158.57 Million over the past twelve months. Generally speaking, earnings are expected to grow in coming quarters. Analysts are forecasting earnings of $-2.36 on a per share basis this quarter. Perhaps, that suggests something about why 94.40% of the outstanding share supply is held by institutional investors.

Technical Analysis

Sometimes, we can understand most about a stock by simply looking at how it has been trading. Looking at the stocks movement on the chart, Puma Biotechnology, Inc. recorded a 52-week high of $98.85. It is now trading 6.8% off that level. The stock is trading $87.01 its 50-day moving average by -5.04%. The stock carved out a 52-week low down at $28.35.

In recent action, Puma Biotechnology, Inc. (PBYI) has made a move of +3.20% over the past month, which has come on Strong relative transaction volume. Over the trailing year, the stock is outperforming the S&P 500 by 47.04, and its gotten there by action that has been less volatile on a day-to-day basis than most other stocks on the exchange. In terms of the mechanics underlying that movement, traders will want to note that the stock is trading on a float of 19.78% with $32.23 Million sitting short, betting on future declines. That suggests something of the likelihood of a short squeeze in shares of PBYI.

See the article here:
Puma Biotechnology, Inc. (PBYI): From Top to Bottom - StockNewsJournal

Puma Biotechnology to Participate in Panel Discussion at Citi’s Biotech Conference – Business Wire (press release)

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will participate in a panel discussion on breast cancer at 9:00 a.m. EDT on Wednesday, September 6, at Citis 12th Annual Biotech Conference in Boston.

A live webcast of the panel discussion will be available on the Companys website at http://www.pumabiotechnology.com. The discussion will be archived on the website and available for 30 days.

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. The Company in-licenses the global development and commercialization rights to three drug candidates PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357. NERLYNX (neratinib) is approved for commercial use by prescription in the United States as extended adjuvant therapy for early stage HER2-positive breast cancer following adjuvant trastuzumab-based therapy and is marketed as NERLYNX. Neratinib is a potent irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2 and HER4. Currently, the Company is primarily focused on the commercialization of NERLYNX and the continued development of its other advanced drug candidates directed at the treatment of HER2-positive breast cancer. The Company believes that NERLYNX has clinical application in the potential treatment of several other cancers that over-express or have a mutation in HER2.

Further information about Puma Biotechnology may be found at http://www.pumabiotechnology.com.

Forward-Looking Statements

This press release and the webcast of the panel discussion contain forward-looking statements, including statements regarding the benefits of NERLYNX and neratinib, the Companys clinical trials and the announcement of data relative to those trials. All forward-looking statements involve risks and uncertainties that could cause the Companys actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors, which include, but are not limited to, the risk factors disclosed in the periodic and current reports filed by the Company with the Securities and Exchange Commission from time to time, including the Companys Quarterly Report on Form 10-Q for the quarter ended June 30, 2017. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company assumes no obligation to update these forward-looking statements, except as required by law.

See more here:
Puma Biotechnology to Participate in Panel Discussion at Citi's Biotech Conference - Business Wire (press release)

CAR-T: Novartis prices CTL019 at US$475000 – European Biotechnology

Swiss Novartis AG has received US market authorisation for its first-in-class CAR-T cell therapy Kymriah (tisagenlecleucel-T). As severe cytokine storms seemed to be generally linked to CAR-T therapies such as Kymriah, the FDA also authorised Roches anti-IL-6R antibody Actemra (tocilizumab) as first-in-class treatment to manage them.

Novartis, which received unanimous backing from the FDA ODAC committee for its CAR-T cell therapy in Julyto treat young patients with acute lymphoblastic leukemia (ALL), priced Kymriah at US$475,000 per patient, making it one of the most expensive treatments in the world. The pharma major also agreed with the CMS (US Centers for Medicare & Medicaid Services) that patients who do not respond to its therapy wont be charged. Kymriah consists of autologous T cells which were engineered ex vivoto target the CD19 antigen on B lymphocytes. As the CD19 antibody is linked to a immunostimulatory CD3zeta/CD137 signalling domain, T cells kill B lymphocytes upon binding.

The Novartis CAR-T approval is a significant progress for patients and patient communities of the diseases that late-stage clinical CAR-T therapies are targeting, commented the International Society for Cellular Therapy. Besides ALL, Novartis is seeking approval for tisagenlecleucel-T in non-hodgkin lymphoma and diffuse large B cell lymphoma. In September, the FDA will decide over market authorisation of Kite Pharmas CAR-T cell therapy axicabtagene ciloleucel targeting the CD19 antigen on B lymphocytes.Most recently, the company has been subject to a US$11.9bn take-over bid by Gilead Sciences.

FDA approval for Novartis breakthrough therapy was based on the ELIANA trial in which tisagenlecleucel-T showed a remission rate of more than 80% in 63 ALL patients at three months. As up to now, four deaths caused by CAR-T induced cytokine release syndrome (CRS) occured in clinical trails evaluating different CAR-T therapies. Since additional 44% of patients who were enroled in the ELIANA trial showed grade 3 and 4 CRS, the FDA also expanded the label of Roche/Genentechs RA antibodytocilizumab (Actemra) to treat CAR T cell-induced CRS. Actemra helped 69% of patients to resolve CRS 14 days after they received the monoclonal antibody. Until today, there has never been an FDA-approved treatment to manage severe cytokine release syndrome associated with CAR T cell therapy, which is marked by a rapid onset and can cause life-threatening complications, said Sandra Horning, MD, Chief Medical Officer and Head of Global Product Development at Roche. Today's approval of Actemra/RoActemra for CRS provides physicians with an important tool to help manage this potentially life-threatening side effect.

According to the FDA, Kymria must be co-administered with Roches immunosuppressive antibody therapy for management of CRS. However, Actemra could not resolve neurotoxicity of tisagenlecleucel-T treatment, which occured in 44% of patients in the ELIANA trial. As manufacturing of Novartis CAR-T cell therapy is lenghty, complicated and only partly reproducible, the 20-25 medical centre expected by Novaertis set to offer the therapy must receive certification before.

Excerpt from:
CAR-T: Novartis prices CTL019 at US$475000 - European Biotechnology

Hofstra and Northwell rename medical school following $61 million donation – The Island Now

Donald and Barbara Zuckers foundation donated $61 million to the medical school founded by Hofstra University and Northwell Health, the organizations announced on Wednesday, leading to renaming the school for the couple.

Most of the donation or $50 million will go towards a permanent endowment to provide students need-based scholarship support in the Zucker School of Medicine.

Some $10 million meanwhile goes towards creating and endowing the Barbara Hrbek Zucker Emerging Scientists Program at the Feinstein Institute for Medical Research, which is headquartered in Manhasset.

The program is intended to prepare postdoctoral fellows for successful careers and support early career faculty in developing research programs.

More so than any other donors in our history, Don and Barbara Zucker have been extraordinary supporters of causes where we have historically struggled to get financial support, Michael J. Dowling, president and chief executive officer of Northwell Health, said in a statement.

Their latest gifts are a testament to the Zuckers leadership as philanthropists who recognize the vital role of medical education and research in transforming the future of medicine.

Donald Zucker, 86, a New York City real estate developer from Sands Point, and his wife Barbara, donated to Northwell in the past. The couple gave to organizations like the Zucker Hillside Hospital in Glen Oaks, Lenox Hill Hospital in Manhattan and the Elmezzi Graduate School of Molecular Medicine in Manhasset.

Lawrence Smith, the founding dean of the Zucker School of Medicine and physician-in-chief at Northwell Health, said that the couple recognized how important it is to support students financially.

Their generosity will ensure that our medical school will continue to be represented by a highly diverse, talented student body that reflects the communities we serve throughout the New York metropolitan area, Smith said.

Hofstra University and Northwell Health first launched the medical school in 2008. It currently has 400 students enrolled and had more than 7,000 applicants competing for 100 spaces in 2016.

Almost a decade ago, we set out to create a new model of medical education that would improve health care in our region and today we mark another milestone in that journey, said Stuart Rabinowitz, the president of Hofstra University. The Zuckers support solidifies and expands our commitment to train innovative physicians whose backgrounds and experiences are as diverse as the people they treat.

Continued here:
Hofstra and Northwell rename medical school following $61 million donation - The Island Now

First genetic engineering therapy approved by the FDA for leukemia – Ars Technica

Enlarge / Scanning electron micrograph of a human T cell.

For the first time, the Food and Drug Administration has approved a therapy that involves genetically engineering a patients own cells, the agency announced Wednesday.

The therapy, called Kymriah (tisagenlecleucel) by Novartis, will be used to reprogram the immune cells of pediatric and young adult patients with a certain type of leukemia, called B-cell acute lymphoblastic leukemia. During a 22-day out-of-body retraining, patients immune cellsspecifically T cells that patrol the body and destroy enemiesget a new gene that allows them to identify and attack the leukemia cells.

Such therapies, called CAR-T therapies, have shown potential for effectively knocking back cancers in several trials, raising hopes of researchers and patients alike. But they come with severe safety concernsplus potentially hefty price tags.

Nevertheless, the FDA announced its approval with fanfare and optimism, calling it a historic action. In the announcement, FDA Commissioner Scott Gottlieb said:

Were entering a new frontier in medical innovation with the ability to reprogram a patients own cells to attack a deadly cancer. New technologies such as gene and cell therapies hold out the potential to transform medicine and create an inflection point in our ability to treat and even cure many intractable illnesses. At the FDA, were committed to helping expedite the development and review of groundbreaking treatments that have the potential to be life-saving.

Like all CAR-T therapies, Kymriah involves reprograming body-guard T cells to contain a gene that codes for a protein called chimeric antigen receptor or CAR. This protein allows the T cells to recognize and attack cells that have a protein called CD19 hanging off themwhich leukemia cells do.

In the Kymriah procedure, researchers first harvest T cells from a patient and then send them to a manufacturing center. There, researchers insert the CAR gene into the immune cells using a virus. The process takes 22 days, Nature reported.

In an earlier trial, 52 of 63 participants (82.5 percent) achieved overall remission after undergoing the therapy. The trial is unpublished and lacked controls, so its not possible to determine Kymriahs influence. But trials of other CAR-T therapies have shown similarly high rates of remission. And the early results were enough to sway an external panel of FDA scientific advisors in July. In a unanimous vote on July 12, the panel recommended that the FDA approve Kymriah.

This is a major advance and is ushering in a new era, panel member Malcolm Smith, a pediatric oncologist at the US National Institutes of Health in Bethesda, Maryland, told Nature at the time.

But, the story isnt all rosy. CAR-T therapies are known to cause life-threatening immune responses called cytokine storms or cytokine release syndrome (CRS). This can lead to systemic full body inflammation, with organ failure, seizures, delirium, and brain swelling. Several trials of therapies similar to Kymriah have reported deaths.

In the Kymriah trial, 47 percent of patients experienced some level of CRS, but none died. Novartis reported that it was able to manage all the cases of CRS.

The FDA noted the risk in todays announcement and also revealed that it had expanded the approved use of a drug called Actemra, which treats CRS, so it can be used in patients who receive CAR-T therapy. The FDA also approved Kymriah with a risk evaluation and mitigation strategy or (REMS). This involves additional safeguards such as extra training and protocols for healthcare providers.

For now, though, Kymriah is only approved for use in patients aged 25 or younger who have failed conventional therapies or relapsed since undergoing those therapies. Of the roughly 3,100 patients aged 20 or younger who are diagnosed each year with acute lymphoblastic leukemia, about 15 to 20 percent will fail treatment. For these patients, Kymriah may be a literal life-saver, as there are few alternatives.

But along with the frightening side effects, gene therapy may also come with a hefty price tag. UK experts have appraised one round of therapy at $649,000. Its still unclear what the actual cost will be and what patients will end up having to pay.

In a press release, Novartis announced that its working with Centers for Medicare and Medicaid Services to come up with outcomes-based pricing. Also in the release, Bruno Strigini, CEO of Novartis Oncology, added:

We are so proud to be part of this historic moment in cancer treatment and are deeply grateful to our researchers, collaborators, and the patients and families who participated in the Kymriah clinical program. As a breakthrough immunocellular therapy for children and young adults who desperately need new options, Kymriah truly embodies our mission to discover new ways to improve patient outcomes and the way cancer is treated.

See the original post here:
First genetic engineering therapy approved by the FDA for leukemia - Ars Technica

Nanomedicine Market Growth Opportunities for Distributers 2017 – Equity Insider (press release)

Global Nanomedicine Market Research Report 2017 to 2022 provides a unique tool for evaluating the market, highlighting opportunities, and supporting strategic and tactical decision-making. This report recognizes that in this rapidly-evolving and competitive environment, up-to-date marketing information is essential to monitor performance and make critical decisions for growth and profitability. It provides information on trends and developments, and focuses on markets and materials, capacities and technologies, and on the changing structure of the Nanomedicine Market.

Companies Mentioned are GE Healthcare, Johnson & Johnson, Mallinckrodt plc, Merck & Co. Inc., Nanosphere Inc., Pfizer Inc., Sigma-Tau Pharmaceuticals Inc., Smith & Nephew PLC, Stryker Corp, Teva Pharmaceutical Industries Ltd., UCB (Union chimique belge) S.A.

Primary sources are mainly industry experts from core and related industries, and suppliers, manufacturers, distributors, service providers, and organizations related to all segments of the industrys supply chain. The bottom-up approach was used to estimate the global market size of Nanomedicine based on end-use industry and region, in terms of value. With the data triangulation procedure and validation of data through primary interviews, the exact values of the overall parent market, and individual market sizes were determined and confirmed in this study.

Sample/Inquire at: https://www.marketinsightsreports.com/reports/08308548/global-nanomedicine-market-research-report-2017/inquiry

This report segments the global Nanomedicine market on the basis of types Regenerative Medicine, In-vitro & In-vivo Diagnostics, Vaccines, Drug Delivery. On the basis of application Clinical Cardiology, Urology, Genetics, Orthopedics, Ophthalmology.

Essential points covered in Global Nanomedicine Market 2017 Research are:-

This independent 116 page report guarantees you will remain better informed than your competition. With over 170 tables and figures examining the Nanomedicine market, the report gives you a visual, one-stop breakdown of the leading products, submarkets and market leaders market revenue forecasts as well as analysis to 2022.

The global Nanomedicine market consists of different international, regional, and local vendors. The market competition is foreseen to grow higher with the rise in technological innovation and M&A activities in the future. Moreover, many local and regional vendors are offering specific application products for varied end-users. The new vendor entrants in the market are finding it hard to compete with the international vendors based on quality, reliability, and innovations in technology.

Browse Full Report at: https://www.marketinsightsreports.com/reports/08308548/global-nanomedicine-market-research-report-2017

Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), and market share and growth rate of Storage Area Network Switch in these regions, from 2012 to 2022 (forecast), covering

by Regions

The report provides a basic overview of the Nanomedicine industry including definitions, classifications, applications and industry chain structure. And development policies and plans are discussed as well as manufacturing processes and cost structures.

Then, the report focuses on global major leading industry players with information such as company profiles, product picture and specifications, sales, market share and contact information. Whats more, the Nanomedicine industry development trends and marketing channels are analyzed.

The research includes historic data from 2012 to 2016 and forecasts until 2022 which makes the reports an invaluable resource for industry executives, marketing, sales and product managers, consultants, analysts, and other people looking for key industry data in readily accessible documents with clearly presented tables and graphs. The report will make detailed analysis mainly on above questions and in-depth research on the development environment, market size, development trend, operation situation and future development trend of Nanomedicine on the basis of stating current situation of the industry in 2017 so as to make comprehensive organization and judgment on the competition situation and development trend of Nanomedicine Market and assist manufacturers and investment organization to better grasp the development course of Nanomedicine Market.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

There are 15 Chapters to deeply display the global Nanomedicine market.

Chapter 1, to describe Nanomedicine Introduction, product scope, market overview, market opportunities, market risk, market driving force;

Chapter 2, to analyze the top manufacturers of Nanomedicine, with sales, revenue, and price of Nanomedicine, in 2016and 2017;

Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016and 2017;

Chapter 4, to show the global market by regions, with sales, revenue and market share of Nanomedicine, for each region, from 2012to 2017;

Chapter 5, 6, 7,8and 9, to analyze the key regions, with sales, revenue and market share by key countries in these regions;

Chapter 10and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2012 to 2017;

Chapter 12, Nanomedicine market forecast, by regions, type and application, with sales and revenue, from 2017to 2022;

Chapter 13, 14 and 15, to describe Nanomedicine sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source.

View post:
Nanomedicine Market Growth Opportunities for Distributers 2017 - Equity Insider (press release)

Daily Corinthian – What still unites us – Daily Corinthian (subscription)

Decades ago, a debate over what kind of nation America is roiled the conservative movement.

Neocons claimed America was an "ideological nation" a "creedal nation," dedicated to the proposition that "all men are created equal."

Expropriating the biblical mandate, "Go forth and teach all nations!" they divinized democracy and made the conversion of mankind to the democratic faith their mission here on earth.

With his global crusade for democracy, George W. Bush bought into all this. Result: Ashes in our mouths and a series of foreign policy disasters, beginning with Afghanistan and Iraq.

Behind the Trumpian slogan "America First" lay a conviction that, with the Cold War over and the real ideological nation, the USSR, shattered into pieces along ethnic lines, it was time for America to come home.

Contra the neocons, traditionalists argued that, while America was uniquely great, the nation was united by faith, culture, language, history, heroes, holidays, mores, manners, customs and traditions. A common feature of Americans, black and white, was pride in belonging to a people that had achieved so much.

The insight attributed to Alexis de Tocqueville -- "America is great because she is good, and if America ceases to be good, she will cease to be great" -- was a belief shared by almost all.

What makes our future appear problematic is that what once united us now divides us. While Presidents Wilson and Truman declared us to be a "Christian nation," Christianity has been purged from our public life and sheds believers every decade. Atheism and agnosticism are growing rapidly, especially among the young.

Traditional morality, grounded in Christianity, is being discarded. Half of all marriages end in divorce. Four-in-10 children are born out of wedlock. Unrestricted abortion and same-sex marriage -- once regarded as marks of decadence and decline -- are now seen as human rights and the hallmarks of social progress.

Tens of millions of us do not speak English. Where most of our music used to be classic, popular, country and western, and jazz, much of it now contains rutting lyrics that used to be unprintable.

Where we used to have three national networks, we have three 24-hour cable news channels and a thousand websites that reinforce our clashing beliefs on morality, culture, politics and race.

Consider but a few events post-Charlottesville.

"Murderer" was painted on the San Fernando statue of Fr. Junipero Serra, the Franciscan who founded the missions that became San Diego, San Francisco, San Juan Capistrano and Santa Clara.

America's oldest monument honoring Columbus, in Baltimore, was vandalized. Sen. Tim Kaine of Virginia called for Robert E. Lee's statue to be removed from Capitol and replaced by -- Pocahontas.

According to legend, this daughter of Chief Powhatan saved Captain John Smith from being beheaded by throwing herself across his neck. The Chief was a "person of interest" in the disappearance of the "Lost Colony" of Roanoke Island, among whose missing was Virginia Dare, the first European baby born in British America.

Why did Kaine not call for John Smith himself, leader of the Jamestown Colony that fought off Indian attacks, to be so honored?

In New Orleans, "Tear It Down" was spray-painted on a statue of Joan of Arc, a gift from France in 1972. Besides being a canonized saint in the Catholic Church and a legendary heroine of France, what did the Maid of Orleans do to deserve this?

Taken together, we are seeing the discoverers, explorers and missionaries of North America demonized as genocidal racists all. The Founding Fathers are either slave owners or sanctioners of slavery.

Our nation-builders either collaborated in or condoned the ethnic cleansing of Native Americans. Almost to the present, ours was a land where segregationists were honored leaders.

Bottom line for the left: Americans should be sickened and ashamed of the history that made us the world's greatest nation. And we should acknowledge our ancestors' guilt by tearing down any and all monuments and statues that memorialize them.

This rising segment of America, full of self-righteous rage, is determined to blacken the memory of those who have gone before us.

To another slice of America, much of the celebrated social and moral "progress" of recent decades induces a sense of nausea, summarized in the lament, "This isn't the country we grew up in."

Hillary Clinton famously described this segment of America as a "basket of deplorables ... racist, sexist, homophobic, xenophobic, Islamaphobic ... bigots," and altogether "irredeemable."

So, what still unites us? What holds us together into the indefinite future? What makes us one nation and one people? What do we offer mankind, as nations seem to recoil from what we are becoming, and are instead eager to build their futures on the basis of ethnonationalism and fundamentalist faith?

If advanced democracy has produced the disintegration of a nation that we see around us, what is the compelling case for it?

A sixth of the way through the 21st century, what is there to make us believe this will be the Second American Century?

Patrick J. Buchanan is the author of a new book, "Nixon's White House Wars: The Battles That Made and Broke a President and Divided America Forever."

Here is the original post:
Daily Corinthian - What still unites us - Daily Corinthian (subscription)

Mnoa volcanologists receive top international awards – UH System Current News

Two volcanologists from the University of Hawaii at Mnoas Department of Geology and Geophysics have received two of the top three awards from the International Association of Volcanology and Chemistry of the Earths Interior (IAVCEI). Bruce Houghton, the Gordon A. MacDonald Professor of Volcanology and science director of the National Disaster Preparedness Training Center at UH Mnoa was honored recently with the IAVCEI Thorarinsson Medal. Sbastien Biass, a post-doctoral researcher, was honored George Walker Medal.

Bruce Houghton near Ruapehu, New Zealand.

The Thorarinsson Medal is awarded only once every four years by IAVCEI for outstanding contributions to volcanology, and is the highest award in international volcanology.

A giant of volcanology, Bruce has tackled big problems in geology with innovative approaches and technologies, and is truly a scientist of outstanding distinction, stated University of Tasmanias Rebecca Carey in her nomination letter. His research has not only generated a wealth of new scientific understanding, but also critically Thorarinsson-type pioneering advances in long-standing cornerstone volcanologic concepts.

Further, Houghton has pioneered research across the interface of fundamental volcanological science and hazards, social and behavioral science, leading to a world-first detailed training course for scientists, first responders and emergency managers, titled the U.S. FEMA Volcanic Crisis Awareness course.

Houghton and his predecessor at UH Mnoa, George Walker, are among the only nine volcanologists to-date given the Thorarinsson award, an award named for the noted Icelandic geologist and volcanologist Sigurdur Thorarinsson.

Houghton reflected on becoming a Thorarinsson Medalist; I was delighted and surprised by the award. All my research is collaborative and, since moving to UH 70 percent of my papers have been first-authored by my students or postdocs, and these are not the type of statistics that usually lead to such awards. I was particularly pleased because allthree of my mentors in volcanology are in the list of eight prior winners of the medal; it is quite humbling to be joining them. For UH to have been awarded two of the nine Thorarinsson Medal to-date is, I think, a sign that volcanology is in excellent health here in Hawaii. The challenge now is to find ways to build on this reputation and capture for UH some of the wonderful crop of young volcanologists on the market.

Sbastien Biass

The George Walker Awardis given every two years to a young scientist up to seven years after acquiring a doctoral degree. The award recognizes achievements of a recent outstanding graduate in the fields of research encompassed by IAVCEI.

Biass, post-doctoral researcher working with Houghton at UH Mnoa School of Ocean and Earth Science and Technology, was honored for achievements that are all deeply rooted in field studies and because of his unique appreciation with the importance of statistical and critical treatment of field data within the growing field of numerical modelling, cited professor Costanza Bonadonna of the University of Geneva. His unique approach, stems from combining thorough field studies with state-of-the-art numerical modeling, furthering both deposit characterization and the newly-born discipline of hazard and risk assessment that he is pioneering. What makes Sbastien unique in his science is his open mind and multidisciplinary approach, his scientific curiosity and enthusiasm and his dedication to going beyond his own limits.

Biass commented, My vision of the IAVCEI George Walker Award for early career scientist is closely tied to my vision of scientific research, which contains three components. First, scientific curiosity is one of the greatest source of pleasure in life and provides the motivation to attempt understanding the unknown. Second, luck, in the selection of work colleagues, has been an integral part of my research. Specifically, Costanza Bonadonna and Bruce Houghton, both part of the UH family in either past or present, have shown me how working on interesting science with bright people is an invaluable source of satisfaction. Thirdly, I see research as having a global objective of the wellbeing of society, which in volcanology translates to a better understanding of the physics of hazardous processes occurring during eruptions in order to mitigate better the impacts on exposed communities. This award therefore represents a success on these three levels and belongs as much to everyone I have ever looked up to as it does to me. Having been picked amongst a long list of such successful young scientists humbles me and gives great motivation to pursue my scientific career.

The award honors the memory of former UH Mnoa geology professor George Walker, whose discoveries pioneered a modern quantitative approach to physical volcanology and greatly accelerated understanding of volcanic processes.

Originally posted here:
Mnoa volcanologists receive top international awards - UH System Current News

Developing technology with advisors at heart – Financial Planning

DALLAS They are young and committed to the technology they've spent years and their own money developing. But unlike some other fintech entrepreneurs, they have no ambition to upend wealth management.

Assembled at the annual conference for the XY Planning Network, some of the finalists vying for top prize in its fintech competition are in fact RIAs themselves.

Mark Friedenthal is both president of an eponymously-named RIA firm in New Jersey and CEO of Tolerisk, a startup he launched to develop better risk assessment software for advisors.

Jantz Hoffman runs his Washington-state based RIA, a non-profit and a startup called CSLA Tech, developing a tool for advisors to better help clients struggling with student debt.

They balance the multiple roles, driven by common beliefs that advisors need better technology to stay competitive and that they can help them better than anyone else.

"The top of the class understands they need to embrace technology," Friedenthal says. "It's very difficult to provide competitive advice without technology. But it is easier and becoming more intuitive to use for advisors and clients."

Hoffman agrees, adding that advisors will need new tech tools to address the needs of the next generation of wealth management clients. "We want to teach others what I've learned," he says. "We want to be able to provide them with a tool to do the work."

Friedenthal, who says one of the key innovations in his software is its ability to perform two levels of risk tolerance, sees all advisors working for the best interests of clients.

"We've made a big bet that the future of advice and planning is entrenched in the fiduciary standard and culture," he says. "If you believe that's the future, everybody is going to need technology to do that."

Motivating Hoffman is his idea that RIAs are best situated to help young investors burdened by large amounts of student debt, a client that the industry has traditionally shunned, he says.

"It's short-sighted, as everyone now has student loans," he says. "The old guard doesn't see the big picture. The assets will come. I have nurses, teachers, doctors, lawyers, all have tons of debt. But if I can help them minimize that, I'll have built those relationships, and that will help me build assets."

LABOR OF LOVEThe effort to bring better behavioral science to advisors is partly a personal mission for Sarah Stanley Fallaw, whose platform DataPoints is based on the work done by her father, Thomas J. Stanley, which he used to write his best-selling book The Millionaire Next Door.

"It's a labor of love, it is something he would've been proud of," Fallaw says. "He would want to get this in the hands of people to improve the way they live their lives."

Fallaw sees advisors opening up to the potential of behavioral finance tools and data as they look for ways to provide more insightful advice.

"They are slowly changing to where they value science," she says. "You can pinpoint behaviors that an advisor can use to help coach clients. Talking about spending is not as exciting as investment returns, but it gets at the heart of how well an individual is managing their life."

Advisors can better manage their practices too, says Elsa Chan, senior vice president of business development at Vestwell, a digital retirement platform.

Coming to wealth management, Chan realized how much advisors have to take on and why they need better tools.

"They are all entrepreneurs themselves, all working for commissions," Chan says. "I was amazed at the amount of work that they have to do just to set up and build the business. Helping them grow their business is very rewarding."

She hopes that the advisor tech industry can adopt the collaborative tone she found among her competitors, particularly around integration.

"There are different options out there for advisors, but a lot of tools are siloed," she says. "Advisors do not want a login for every tool; they want a single dashboard to their clients and to be able to efficiently manage those assets through one platform."

Suleman Din is managing editor of SourceMedia's Investment Advisor Group. Follow him on Twitter at @sulemandn

See the original post:
Developing technology with advisors at heart - Financial Planning

Sales Incentives and Machine Learning: Intelligently Motivate Revenue-Driving Behaviors – Customer Think

Imagine you are trying to get children to do household chores for the summer. You decide to offer them an incentive of $5 per completed chore. At the beginning of summer, this works great; work is getting done and the kids enjoy the reward. However, after a few weeks, the system has fallen apart. The children only do the chores they enjoy, they neglect other jobs, and the quality of their work has decreased. Should you change the reward amount? Should different chores have different incentives? Should each child receive different rewards? Did this system work better last year? What do your neighbors do to get their kids to do chores?

In this simple example of human behavior, there is a broken incentive system and a lack of data to help determine how things should change. This scenario is not a far comparison to many organizations sales compensation systems. Every year, new compensation plans roll out to the sales teams who go out and sell based on how they believe they will be compensated. As of 2017, 90 percent of U.S. companies change their compensation plans on an annual basis. But are these adjustments optimal are they going to lead to desired business outcomes? Is there a better way to identify which changes need to be made, and when to make them?

Traditionally, sales compensation changes are based more on intuition than data, but often there is some level of analysis that goes into designing and adjusting incentives. However, most reports today are all hindsight and adjustments are made well after there is any potential to change behavior before the end of the quarter or end of the year. What if optimal changes could be identified mid-period and put in place well before it is too late? Better yet, what if the incentive compensation solution itself could identify, recommend and implement plan changes? The most practical way to do this is with machine learning.

The concept of machine learning is not exactly new in the world of technology. It has been around in a variety of forms for decades, but its application to enterprise software is relatively new, particularly with sales incentive management, and its popularity is growing. There are many factors making machine learning realistically applicable in the business world changes in the economics of cloud computing (cheaper than ever before), cloud storage, proliferation of sensors driving Internet of Things (IoT), pervasive use of mobile devices that consume gigabytes of data in minutes, and freely available algorithms are all major contributors to accelerating machine learning adoption. Add to these the complex problems companies face including managing sales compensation, and the perfect environment is in place for machine learning to dramatically proliferate.

Machine learning is all about applying learned data to prescribe more economically efficient business decisions. Sales incentives apply the disciplines of psychology and behavioral economics to prompt people to make desired decisions. When you combine principles of behavioral economics with the data science of machine learning, you create the potential to optimize your sales incentives and drive powerful business outcomes.

Machine learning allows us to assess large sets of data and surface patterns, identifying when past performance is indicative of future results. For instance, machine learning can accurately forecast what products are most likely to be sold and which customers are most likely to buy. But what if you not only want to understand potential outcomes, what if you want to completely change outcomes?

What is going to motivate your sales team to do what you need them to? The difference between expectations and reality is often referred to as the behavioral gap (see chart below). When the behavioral gap is significant, an inflection point is needed to close that gap. The right incentive (an added bonus, Presidents Club eligibility, a promotion, etc.) can initiate an inflection point and influence a change in behavior.

The behavior gap depicted above represents the difference between raised expectations (management increasing quota) and the trajectory of current sales performance.

In the US, studies from Harvard Business Review and other industry publications estimate that companies spend over one trillion dollars annually on incentives. That number is four times the money spent on advertising in the US annually. What that means is that, as a nation, we are deeply invested in motivating our employees, partners and customers. Incentives are most effective when they are intelligent, or data driven. Deloitte University Press published a report stating that when it comes to the relationship between data science and behavioral science, it is reasonable to anticipate better results when the two approaches are treated as complementary and applied in tandem. Behavioral science principles should be part of the data scientists toolkit, and vice versa.

With Machine learning and behavior mechanics, sales teams can plot out the path from one goal to the next and analyze and implement proper incentives. As an example, lets say your company is a furniture manufacturer that uses a CPQ tool to manage its complex quoting and pricing processes. One of the major reasons your company invested in the CPQ solution was to curb chronic, costly discounting by the sales team. You are a new sales rep using CPQ to build a quote. What if, mid-quote, your system alerts you that the discount you entered, while within the approved range, may not be ideal. Machine learning ran in the background and identified a different discount used by the top 10% of reps that has had more success. Additionally, you learn that if you choose the prescribed discount, you will earn 40% more commission! Talk about a relevant incentive, based on powerful data.

When applied together, machine learning and sales incentives provide powerful business results by collecting relevant, timely insight and defining incentives that align human behaviors with organizational goals.

Original post:
Sales Incentives and Machine Learning: Intelligently Motivate Revenue-Driving Behaviors - Customer Think